The Ultimate Resource for Pharmaceutical SOPs and Best Practices
To define a standardized approach for the periodic review of expression cell lines used in biosimilar product development and manufacturing to ensure genetic stability, expression consistency, and ongoing regulatory compliance.
Click to read the full article.
To define the procedure for harmonizing Master Cell Bank (MCB) and Working Cell Bank (WCB) data with Quality Assurance (QA) systems in biosimilar development, ensuring consistent documentation, traceability, and GMP compliance.
Click to read the full article.
To establish a validated, secure, and compliant method for the transportation of Master Cell Bank (MCB) and Working Cell Bank (WCB) materials from one facility to another within or outside the organization, ensuring viability, identity, and containment during transit.
Click to read the full article.
To outline a systematic process for maintaining the audit readiness of documentation generated during Cell Line Development (CLD) in biosimilar manufacturing, ensuring compliance with regulatory requirements and internal QA standards.
Click to read the full article.
To establish a systematic approach for identifying and resolving transfection failures encountered during biosimilar cell line development to ensure optimal gene delivery efficiency and reproducibility.
Click to read the full article.
To define a systematic approach for preserving data integrity in all Cell Line Development (CLD) operations associated with biosimilar research and manufacturing by following ALCOA+ principles and current GMP requirements.
Click to read the full article.
To establish a standardized training process for all personnel involved in Cell Line Development (CLD) operations in biosimilar manufacturing, ensuring technical competence, regulatory awareness, and compliance with GMP practices.
Click to read the full article.
To establish a standardized procedure for the review, approval, and archival of Cell Line Development (CLD) protocols used during biosimilar product development, ensuring scientific validity, documentation control, and regulatory alignment.
Click to read the full article.
To outline the methodology for defining, measuring, analyzing, and documenting clone performance metrics during the Cell Line Development (CLD) stage of biosimilar manufacturing.
Click to read the full article.
To establish a structured framework for the phase-gate review process for biosimilar cell lines, enabling objective evaluation at each developmental stage and decision-making based on predefined scientific and quality criteria.
Click to read the full article.